Inicio
Resultado de la búsqueda
12 búsqueda de la palabra clave 'temozolomide'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update / Luis Vicente Syro Moreno
Título : 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Endocrine Related Cancer
Idioma : Inglés (eng)
Palabras clave : Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000800 AC-2018-087 Archivo digital Producción Científica Artículos científicos Disponible
Título : Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents chemotherapy DNA repair neoplasms neuroendocrine tumors O(6)-Methylguanine-DNA Methyltransferase pituitary temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Frontiers in Endocrinology
Idioma : Inglés (eng)
Palabras clave : Alkylating agents chemotherapy DNA repair neoplasms neuroendocrine tumors O(6)-Methylguanine-DNA Methyltransferase pituitary temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000777 AC-2018-064 Archivo digital Producción Científica Artículos científicos Disponible
Título : Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Endocrine Pathology Idioma : Inglés (eng) Palabras clave : MGMT pathology pituitary somatotroph adenoma temozolomide Resumen : Improved imaging techniques have contributed to increased diagnosis of pituitary tumors. These tumor types can be microadenomas or macroadenomas and can either be functional or non-functional. Atypical or aggressive pituitary adenomas are tumors that rapidly increase in size and may invade into the suprasellar or parasellar regions. They are characterized by a Ki-67 nuclear labeling index greater than 10 %. Management of these tumors is difficult, and many recur after surgery. Temozolomide, a second generation alkylating agent, has been showing promising results in the treatment of these tumors. The patient was a 39-year-old male diagnosed with an invasive silent somatotroph pituitary macroadenoma treated with temozolomide after surgery. We present the case along with the review of the literature of the therapeutic effects of temozolomide in somatotroph macroadenomas. Mención de responsabilidad : Ali A Ghazi, Fabio Rotondo, Kalman Kovacs, Alireza Amirbaigloo, Luis V Syro, Hussein Fathalla, Antonio Di Ieva, Michael D Cusimano Referencia : Endocr Pathol. 2015 May;26(2):135-9. DOI (Digital Object Identifier) : 10.1007/s12022-015-9361-z PMID : 25716461 En línea : https://link.springer.com/article/10.1007%2Fs12022-015-9361-z Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3882 Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature [documento electrónico] / Luis Vicente Syro Moreno, . - 2015.
Obra : Endocrine Pathology
Idioma : Inglés (eng)
Palabras clave : MGMT pathology pituitary somatotroph adenoma temozolomide Resumen : Improved imaging techniques have contributed to increased diagnosis of pituitary tumors. These tumor types can be microadenomas or macroadenomas and can either be functional or non-functional. Atypical or aggressive pituitary adenomas are tumors that rapidly increase in size and may invade into the suprasellar or parasellar regions. They are characterized by a Ki-67 nuclear labeling index greater than 10 %. Management of these tumors is difficult, and many recur after surgery. Temozolomide, a second generation alkylating agent, has been showing promising results in the treatment of these tumors. The patient was a 39-year-old male diagnosed with an invasive silent somatotroph pituitary macroadenoma treated with temozolomide after surgery. We present the case along with the review of the literature of the therapeutic effects of temozolomide in somatotroph macroadenomas. Mención de responsabilidad : Ali A Ghazi, Fabio Rotondo, Kalman Kovacs, Alireza Amirbaigloo, Luis V Syro, Hussein Fathalla, Antonio Di Ieva, Michael D Cusimano Referencia : Endocr Pathol. 2015 May;26(2):135-9. DOI (Digital Object Identifier) : 10.1007/s12022-015-9361-z PMID : 25716461 En línea : https://link.springer.com/article/10.1007%2Fs12022-015-9361-z Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3882 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000462 AC-2015-015 Archivo digital Producción Científica Artículos científicos Disponible
Título : O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Neurosurgery Idioma : Inglés (eng) Palabras clave : Crooke cell adenoma cushing disease MGMT pituitary adenoma silent corticotroph adenoma temozolomide Resumen : Background: O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that counteracts chemotherapeutic cytotoxicity of alkylating agents such as temozolomide. Low levels of MGMT expression have been shown to correlate with longer survival in glioma patients treated with temozolomide. The same is true in pi- tuitary adenomas. Objective: We investigated the immunohistochemical expression of MGMT in a variety of corticotroph adenoma subtypes to determine the potential utility of temozolomide as a therapeutic agent. Methods: The tumors consisted of 40 cases of adrenocorticotropin-secreting pituitary tumors in Cushing disease, 12 Crooke cell adenomas, and 7 subtype I silent corticotroph adenomas. Staining for MGMT was assessed by light microscopy; nuclear reactivity was estimated semiquantitatively as present in , 10%, 10% to 25%, 25% to 50%, 50% to 75%, and . 75% of cells. Results: Immunoexpression showed no correlation with patient age, sex, tumor size, invasiveness, or recurrence in patients with Cushing disease. Among adrenocorticotropin- ecreting adenomas associated with Cushing disease, most invasive (60%) and recurrent (86%) tumors showed low MGMT immunopositivity, defined as , 25%. Most (75%) Crooke cell adenomas exhibited an MGMT immunoreactivity of # 50%. All sub-type I silent corticotroph adenomas showed , 10% MGMT staining. Conclusion: Our descriptive findings of low MGMT expression in adrenocorticotropin-producing pituitary adenomas, particularly aggressive tumors, suggest that they may be suitable candidates for temozolomide therapy. Mención de responsabilidad : Fateme Salehi, Bernd W Scheithauer, Kalman Kovacs, Eva Horvath, Luis V Syro, Soniya Sharma, Branavan Manoranjan, Michael Cusimano Referencia : Neurosurgery. 2012 Feb;70(2):491-6. DOI (Digital Object Identifier) : 10.1227/NEU.0b013e318230ac63 PMID : 21822153 En línea : https://academic.oup.com/neurosurgery/article-abstract/70/2/491/2744231?redirect [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3633 O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Neurosurgery
Idioma : Inglés (eng)
Palabras clave : Crooke cell adenoma cushing disease MGMT pituitary adenoma silent corticotroph adenoma temozolomide Resumen : Background: O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that counteracts chemotherapeutic cytotoxicity of alkylating agents such as temozolomide. Low levels of MGMT expression have been shown to correlate with longer survival in glioma patients treated with temozolomide. The same is true in pi- tuitary adenomas. Objective: We investigated the immunohistochemical expression of MGMT in a variety of corticotroph adenoma subtypes to determine the potential utility of temozolomide as a therapeutic agent. Methods: The tumors consisted of 40 cases of adrenocorticotropin-secreting pituitary tumors in Cushing disease, 12 Crooke cell adenomas, and 7 subtype I silent corticotroph adenomas. Staining for MGMT was assessed by light microscopy; nuclear reactivity was estimated semiquantitatively as present in , 10%, 10% to 25%, 25% to 50%, 50% to 75%, and . 75% of cells. Results: Immunoexpression showed no correlation with patient age, sex, tumor size, invasiveness, or recurrence in patients with Cushing disease. Among adrenocorticotropin- ecreting adenomas associated with Cushing disease, most invasive (60%) and recurrent (86%) tumors showed low MGMT immunopositivity, defined as , 25%. Most (75%) Crooke cell adenomas exhibited an MGMT immunoreactivity of # 50%. All sub-type I silent corticotroph adenomas showed , 10% MGMT staining. Conclusion: Our descriptive findings of low MGMT expression in adrenocorticotropin-producing pituitary adenomas, particularly aggressive tumors, suggest that they may be suitable candidates for temozolomide therapy. Mención de responsabilidad : Fateme Salehi, Bernd W Scheithauer, Kalman Kovacs, Eva Horvath, Luis V Syro, Soniya Sharma, Branavan Manoranjan, Michael Cusimano Referencia : Neurosurgery. 2012 Feb;70(2):491-6. DOI (Digital Object Identifier) : 10.1227/NEU.0b013e318230ac63 PMID : 21822153 En línea : https://academic.oup.com/neurosurgery/article-abstract/70/2/491/2744231?redirect [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3633 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000204 AC-2012-044 Archivo digital Producción Científica Artículos científicos Disponible
Título : Temozolomide in aggressive pituitary adenomas and carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Clinics (Sao Paulo) Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Temozolomide in aggressive pituitary adenomas and carcinomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Clinics (Sao Paulo)
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000176 AC-2012-016 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalinkPermalinkPermalinkPermalink
